4.6 Review

The heparanase/syndecan-1 axis in cancer: mechanisms and therapies

Journal

FEBS JOURNAL
Volume 280, Issue 10, Pages 2294-2306

Publisher

WILEY
DOI: 10.1111/febs.12168

Keywords

extracellular signal-regulated kinase; heparan sulfate; heparanase; heparin mimics; hepatocyte growth factor; syndecan-1; vascular endothelial growth factor

Funding

  1. NIH [CA135075, CA138340, CA138535]
  2. United States-Israel Binational Science Foundation [2009230]
  3. Division Of Astronomical Sciences
  4. Direct For Mathematical & Physical Scien [2009230] Funding Source: National Science Foundation

Ask authors/readers for more resources

Heparanase is an endoglucuronidase that cleaves heparan sulfate chains of proteoglycans. In many malignancies, high heparanase expression and activity correlate with an aggressive tumour phenotype. A major consequence of heparanase action in cancer is a robust up-regulation of growth factor expression and increased shedding of syndecan-1 (a transmembrane heparan sulfate proteoglycan). Substantial evidence indicates that heparanase and syndecan-1 work together to drive growth factor signalling and regulate cell behaviours that enhance tumour growth, dissemination, angiogenesis and osteolysis. Preclinical and clinical studies have demonstrated that therapies targeting the heparanase/syndecan-1 axis hold promise for blocking the aggressive behaviour of cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available